Feasibility of a Behavioral Activation Trial

Overview

The goal of this project is to train community mental health therapists in behavioral activation (BA) treatment for major depressive disorder and then to conduct a study examining the feasibility of evaluating the effectiveness of BA in this setting.

Full Title of Study: “Feasibility of a Behavioral Activation Trial in Community Mental Health”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Single (Outcomes Assessor)
  • Study Primary Completion Date: November 2019

Detailed Description

After finalizing a 9-session BA treatment model for major depressive disorder in the Community Mental Health Center (CMHC) setting, the final treatment manual will be used to train clinicians in BA at the CMHC through workshops and training cases. Upon completion of training and certification of adequate implementation of BA, a total of 80 patients with MDD will be randomly assigned in a 3:1 ratio to 9 sessions of BA or treatment-as-usual (TAU) at the CMHC. Feasibility will be assessed in terms of (1) percent of eligible patients who refuse randomization, (2) percent of patients who complete 9 sessions of BA treatment, (3) percent of BA homework assignments that are completed, (4) percent of monthly assessments obtained, and (5) patient ratings of credibility and alliance in BA treatment. The ability of CMHC therapists to adequately implement BA will be assessed by rating taped sessions on BA adherence and competence scales. In addition to feasibility/acceptability of BA and TAU, this study is designed to test whether theoretically important targets of BA change over the course of BA treatment, and whether such changes are associated with changes in depressive symptoms. The target measures will be assessed at baseline, month 1, month 2, and month 3. To support the potential role of these targets as the mechanisms of change in BA, change in the target variables will be examined in relation to change in depression symptoms. The investigators will also pilot a potential moderator of treatment effects (trait reward processing, as measured at baseline using the Effort-Expenditure for Rewards Task) to include this potential moderator in a subsequent fully-powered study with the long-term goal of identifying the types of patients most responsive to BA.

Interventions

  • Behavioral: behavioral activation
  • Behavioral: treatment-as-usual
    • psychotherapy (and potentially medication) as part of treatment-as-usual provided in a community mental health center

Arms, Groups and Cohorts

  • Experimental: behavioral activation
    • The core principles of the BA model are: (1) the key to changing how people feel is helping them change what they do, (2) changes in life can lead to depression, and short-term coping strategies may keep people stuck over time, (3) the clues to figuring out what will be antidepressant for a particular client lie in what precedes and follows the client’s important behaviors, (4) structure and scheduling of activities should follow a plan, not a mood, (5) change will be easier when starting small, (6) activities that are naturally reinforcing should be emphasized, (7) the therapist should act as a coach, (8) a problem-solving empirical approach should be emphasized with recognition that all results are useful, (9) patients should be encourages to not just talk, do! (10) possible and actual barriers to activation should be examined. Patients can also receive medications in this arm.
  • Other: treatment-as-usual
    • Patients will receive psychotherapy (and potentially medications) as part of treatment-as-usual provided in the CMHC setting.

Clinical Trial Outcome Measures

Primary Measures

  • percent of eligible patients who refuse randomization
    • Time Frame: assessed at baseline
    • We will calculate this value based on our records of patient participation in baseline assessments.
  • percent of patients who complete 9 sessions of BA treatment
    • Time Frame: 12 weeks
    • We will calculate this value based on our records of patient attendance of therapy sessions (tracked each week by a research assistant).
  • percent of BA homework assignments that are completed
    • Time Frame: 12 weeks
    • We will calculate this value based on our records of homework assignment completion (tracked weekly by therapist participants and reported to the research staff).
  • percent of monthly assessments obtained
    • Time Frame: 12 weeks
    • We will calculate this value based on our records of patient assessment attendance (tracked by a research assistant).
  • Opinions About Treatment questionnaire
    • Time Frame: collected at week 2
    • This questionnaire measures patient ratings of the credibility of BA treatment.
  • Brief Alliance Inventory
    • Time Frame: collected at weeks 2, 4, 6, and 8
    • This questionnaire measures patient ratings of the therapeutic alliance.

Secondary Measures

  • Behavioral Activation for Depression Scale
    • Time Frame: monthly for 3 months
  • Reward Probability Index
    • Time Frame: monthly for 3 months
  • Hamilton Rating Scale for Depression
    • Time Frame: monthly for 3 months
  • Short Form Health Survey (SF-36)
    • Time Frame: monthly for 3 months
  • Inventory of Depressive Symptomatology
    • Time Frame: monthly for 3 months
  • Behavior and Symptom Identification Scale (BASIS-24)
    • Time Frame: monthly for 3 months
  • Dysfunctional Attitudes Scale
    • Time Frame: monthly for 3 months
  • Quality of Life Index (questionnaire)
    • Time Frame: monthly for 3 months
  • Beck Anxiety Inventory
    • Time Frame: monthly for three months
  • Effort Expenditure for Rewards Task (EEfRT)
    • Time Frame: administered once at baseline and once at month 3

Participating in This Clinical Trial

Inclusion Criteria

1. confirmed diagnosis of MDD based on the SCID for DSM-IV (or DSM-V, if available), 2. ability to read at least at the 4th grade level, 3. willingness to participate in research, 4. willingness to be audio recorded (for both therapists and patient- participants) Exclusion Criteria:

1. current or past psychotic disorder, seizure disorder, or clinically significant organic pathology 2. acute medical problem requiring immediate inpatient treatment, 3. current substance abuse or dependence requiring primary referral to substance abuse program, 4. significant suicidal risk/ideation requiring immediate referral or suicidal gesture within the last 3 months

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • University of Pennsylvania
  • Collaborator
    • Merakey Behavioral Health
  • Provider of Information About this Clinical Study
    • Sponsor

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.